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Chorea-acanthocytosis (ChAc) is a hereditary neurodegenerative disorder, one of the 
neuroachantocytosis syndromes (NA). One of the hallmarks of NA is the presence of circulating 
acanthocytes, generation of which is still under investigation. Recently, we reported increased Tyr-
phosphorylation state of the red blood cell (RBC) membrane proteins from ChAc patients, related to 
abnormal activation of Lyn, an Src family kinase (SFKs) (Blood 118; 5652; 2011). In the context of 
international collaboration, we further characterized Lyn signaling pathway in RBC from ChAc 
patients. In ChAc RBCs, we found a weakness of ankyrin-based multiprotein complex bridging the 
membrane to the cytoskeleton, contributing to the generation of acanthocytes. We then evaluated the 
state of Lyn (active-inactive) in the cytoplasmic fraction from RBC of ChAc patients. In ChAc 
RBCs we found higher levels of Phospho- Lyn-396, corresponding to active Lyn, compared to 
controls. We then evaluated whether classical Lyn inhibitors such as PP2 or Dasatinib, a 
pharmacological Lyn inhibitor, might block Lyn in ChAc RBCs. We found that both PP2 (0.1μM) 
or Dasatinib (0.1 μM) were able to efficiently inhibit Lyn in both ChAc and healthy RBCs. These 
data suggest that in ChAc (i) the abnormal activation of Lyn affects RBC membrane mechanical 
stability weakening both multiprotein complexes, bridging the membrane to the cytoskeleton; (ii) 
Lyn activity is inhibited by either PP2 or Dasatinib, suggesting Lyn as possible new therapeutic 
target in ChAc. 
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